Agilent Technologies launches new IQFISH lung cancer panel

Agilent Technologies has announced the European launch of its new IQFISH lung cancer panel, which has been granted CE-IVD approval.

Designed for automated analysis using the Dako Omnis system, the new panel enables routine pathology laboratories to easily integrate fast, high-quality fluorescence in situ hybridisation (FISH) into their immunohistochemistry workflow.

This allows labs to simultaneously stain IHC and FISH slides and enable multiple FISH slides to be processed in just four hours. By contrast, the process often takes two days or more with traditional FISH methods.

The panel consists of ALK, ROS1, RET and MET IQFISH probes and was designed using the groundbreaking, oligonucleotide-based SureFISH technology, making use of the formamide-free IQFISH fast hybridisation buffer.

It is the second IQFISH launch for Dako Omnis, following the introduction of the HER2 IQFISH pharmDx panel last year.

Jacob Thaysen, president of Agilent's diagnostics and genomics group, said: "Agilent is committed to improving the speed and accuracy of patient-sample processing and the quality of test performance. We know that these factors greatly affect treatment decisions and patient outcome."

With over 20 years of experience within the science market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current science roles we have available, you can search for the latest job roles, register your details, or contact the team today.